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Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) is part of antineutrophil cytoplasmic antibodies
(ANCAs)-associated vasculitides. In EGPA small-vessel vasculitis is associated with eosinophilia and asthma. About
40% of EGPA patients are ANCA-positive, suggesting a role for B cells in the pathogenesis of EGPA. B cell-depleting
therapy with rituximab (RTX) can be effective in ANCA-positive EGPA, but very few patients have been published to
date. The role of RTX in the treatment of ANCA-negative EGPA is unclear.
Methods: We report a single-center cohort of patients with eosinophilic granulomatosis with polyangiitis. Of these
patients, nine (six ANCA-positive, three ANCA-negative) had been treated with RTX for relapsing or refractory
disease on standard immunosuppressive treatment. In a retrospective analysis, data on treatment response,
frequency of relapses, adverse events, and peripheral B-cell reconstitution were evaluated. Furthermore, serum
immunoglobulin concentrations, ANCA status, and peripheral B cell subpopulations were assessed after RTX
treatment.
Results: All patients had high disease activity before RTX treatment. At presentation 3 months after RTX therapy, all
ANCA-positive and ANCA-negative patients had responded to RTX, with one patient being in complete remission,
and eight patients being in partial remission. After a mean follow-up of 9 months, C-reactive protein concentrations
had normalized, eosinophils had significantly decreased, and prednisone had been tapered in all patients. In all
patients, RTX therapy was combined with a standard immunosuppressive therapy. Within the 9-month observation
period, no relapse was recorded. Three patients were preemptively retreated with RTX, and during the median
follow-up time of 3 years, no relapse occurred in these patients. During the follow-up of 13 patient-years, five minor
but no major infections were recorded.
Conclusions: In our analysis on nine patients with EGPA resistant to standard therapy, rituximab proved to be an
efficient and safe treatment for ANCA-positive and ANCA-negative patients. Preemptive retreatment with RTX,
combined with standard maintenance immunosuppressants, resulted in a sustained treatment response.
Prospective, randomized trials evaluating the use of RTX in EGPA are warranted.Introduction
ANCA-associated vasculitides (AAVs) are a heterogeneous
group of autoimmune diseases, sharing the feature of
small-vessel vasculitis. The spectrum of AAV comprises
granulomatosis with polyangiitis (GPA), microscopic
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reproduction in any medium, provided the orpolyangiitis (EGPA), the later formerly known as Churg-
Strauss syndrome (CSS). In EGPA small-vessel vasculitis is
associated with eosinophilia and asthma [1]. The clinical
manifestations commonly seen in patients presenting with
EGPA range from upper airway and lung involvement to
neurologic, cardiac, cutaneous, and renal manifestations
[2-4]. The pathogenesis of the disease is incompletely
understood, but an involvement of eosinophils and T lym-
phocytes has been demonstrated [5,6]. In EGPA patients,
the peripheral T-cell compartment is skewed, and EGPA
has been considered to be a Th2-mediated disease. Th2d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tors for eosinophils [7] and eotaxin-3 has been identified
as an eosinophil recruitment factor [8]. Targeting
interleukin-5 with mepolizumab is promising for treat-
ment of EGPA, but has a temporally limited effect. The
conventional treatment of EGPA is based on glucocorti-
coids, which are combined with cyclophosphamide in pa-
tients with serious organ involvement. Depending on
severity of the disease, immunosuppressants like metho-
trexate (MTX) or azathioprine (AZA) can also be used for
remission induction and are often used along with gluco-
corticoids for maintenance therapy. To date, no clear
disease-stage-specific therapy regimen exists for remission
induction and maintenance therapy. The considerable rate
of side effects related to the use of higher doses of gluco-
corticoids or cyclophosphamide, the high rate of relapses
on standard therapy regimens, and the fact that some
EGPA patients either do not respond to CYC therapy or
relapse shortly after CYC treatment underline the need for
alternative therapies [9]. Recent case reports suggest a fa-
vorable effect of the B cell-depleting agent rituximab
(RTX) in EGPA [10-16]. The rationale for introducing a B
cell-depleting therapy into the treatment of EGPA comes
from the observation of myeloperoxidase (MPO)-specific
ANCA in about 40% of EGPA patients [17], but the role
of B cells in the pathogenesis of ANCA-negative EGPA is
less clear. Furthermore, Th2 cells, by producing IL-4 and
IL-13 may sustain the activation of not only eosinophils,
but also B lymphocytes and promote B-cell class switching
to IgE [6]. Eosinophilic granulocytes in turn maintain a vi-
cious cycle of T-cell activation by secreting IL-25 [2]. Add-
itionally, increased serum IgG4 concentrations have been
described in EGPA [18]. RTX can induce remission in
EGPA, but our knowledge on the role of RTX in EGPA is
unfortunately based on a very limited number of case re-
ports. Altogether, in studies reporting exclusively EGPA
patients, fewer than 15 patients treated with RTX have
been reported to date. We report nine EGPA patients
from a single-center cohort that had been treated for re-
lapsing or refractory disease on standard immunosuppres-
sive treatment with RTX. We provide clinical data on
relapse rate, peripheral B-cell reconstitution, and adverse
events. Furthermore, we report on three EGPA patients




Patients included in this study had a diagnosis of EGPA
defined by the Lanham criteria [19], the American College
of Rheumatology criteria [20], or the Chapel Hill Consen-
sus criteria [21]. Furthermore, inclusion required RTX
treatment for relapsing or refractory disease activity and a
minimal follow-up after RTX infusion of 6 months. Thestudy was approved by the ethics committee of the Albert-
Ludwigs-University, Freiburg (file No. 191/11, 46/04).
Written informed consent according to the Declaration of
Helsinki was obtained from all patients.
Study design
Patients included into this retrospective analysis were
evaluated by a rheumatologist for diagnosis, sex, and age
at application of first RTX infusion. Data analyses of the
patients furthermore comprised laboratory values (for
example, differential blood count, creatinine, C-reactive
protein, creatine kinase, troponin T, myoglobin, lactate
dehydrogenase, urine analysis), evaluation of disease ex-
tent, and organ involvement. Results of biopsies were in-
cluded when available. Disease activity was measured by
BVAS (version 3) [22]. The prognostic Five-Factor Score
(FFS) was determined in all patients at first diagnosis of
EGPA [23]. During follow-up after RTX application, pa-
tients were seen regularly every 3 to 6 months and eval-
uated by a rheumatologist.
Definition of disease activity and treatment responses
Complete remission was defined as a BVAS of 0 for at
least 3 months and a stable prednisone dose ≤7.5 mg
prednisone per day. The persistent BVAS (pBVAS) rated
disease status, when patients had some BVAS items that
were not new or worsening but persistent (regressing or
unchanged). A pBVAS >0 was defined to correspond to
partial remission. Treatment response was defined as a
50% reduction of disease-activity score and absence of
new manifestations attributable to ANCA vasculitis. Re-
fractory disease was defined as unchanged or increased
disease activity in acute EGPA after more than 4 weeks
of treatment with standard therapy. Relapse was defined
as the occurrence of ≥1 BVAS item caused by active
AAV after having achieved remission.
Major relapses were defined as the recurrent or new on-
set of potentially life-threatening disease activity that could
not be treated with an increase in glucocorticoids alone.
All other relapses were defined as minor. Low-activity dis-
ease was defined as persistence of minor symptoms (for
example, arthralgia or myalgia) [24].
Analysis of immunoglobulins, ANCA, and peripheral B-cell
numbers
RTX preceding immunosuppressive therapies, standard
maintenance therapies after RTX, and concomitant use
of glucocorticoids were assessed. Immunoglobulin (Ig)
serum concentrations (normal range, IgG, 7 to 16 g/L;
IgM, 0.4 to 2.3 g/L; IgA, 0.7 to 4 g/L; IgE, 10 to 100 IU/
ml) were determined by nephelometry. The ANCA
staining pattern (cytoplasmatic or perinuclear) was
assessed by indirect immunofluorescence (Euroimmun,
Medizinische Labordiagnostika AG, Luebeck, Germany).
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Mainz, Germany) or MPO (Euroimmun, Medizinische
Labordiagnostika AG, Luebeck, Germany) was measured
by enzyme-linked immunosorbent assay (ELISA) and
interpreted according to manufacturers’ reference, with
values <10 IU/ml for PR3 and <20 IU/ml for MPO indi-
cating a negative test. Peripheral B-cell counts were mea-
sured by using a whole-blood staining by flow cytometry
by using a FACS Canto II (BD-Biosciences) and PE-Cy7-
conjugated anti-CD19 (clone:J3.119; Beckman-Coulter).
Results were expressed both as absolute cell counts and
relative percentages with normal ranges, as previously de-
scribed [25]. Depletion of B cells was defined as ≤0.01 ×
109/L or ≤0.5% of total peripheral lymphocytes. The start
of peripheral B-lymphocyte repopulation was defined as B
cells reaching >0.5% of total peripheral lymphocytes or
>0.01 × 109/L.
Antibodies and flow-cytometric analysis of B-lymphocyte
subsets in peripheral blood
PBMCs obtained from EDTA-anticoagulated blood by
Ficoll density centrifugation were stained with the fol-
lowing fluorescent-labeled monoclonal antibodies: FITC-
conjugated mouse-IgG1 (Beckman-Coulter), anti-CD27
(clone, M-T271; DakoCytomation), anti-kappa (clone,
G20-193; BD-Biosciences), anti-CD10 (clone, ALB1;
Beckman-Coulter), PE-conjugated anti-IgD (goat IgG F
(ab)2; SouthernBiotech), anti-IgA (goat IgG F(ab)2;
SouthernBiotech), anti-Lambda (clone, JDC-12; BD Bio-
sciences) and anti-CD21 (clone, B-ly4; BD Biosciences),
PE-Cy7-conjugated anti-CD19 (clone, J3.119; Beckman-
Coulter); PerCP-conjugated anti-CD20 (clone, 2H7;
Biolegend), APC-conjugated anti-CD45 (clone, 2D1; BD
Biosciences), DyLight649-conjugated anti-IgM (goat IgG
F(ab)2; Jackson ImmunoResearch Laboratories) and
PacificBlue-conjugated anti-CD38 (clone, HIT2; EXBIO).
Immediately after isolation of cells, staining and flow-
cytometric analysis were performed by using a FACS
Canto II (BD Biosciences). After proper calibration by
standard fluorescent beads, acquisition and analysis of
5,000 to 10,000 B cells were performed by gating on
CD19+ events and lymphocyte characteristics by using
both forward and sideward scatter, supported by the
DIVA software (BD Biosciences). The following B-cell
subsets were distinguished:
Total B cells, CD19+
Naïve B cells, CD19+IgDhighIgM+CD27-
Transitional B cells, CD19+CD27-CD10+CD38+IgMhigh
IgDhigh
Marginal zone B cells, CD19+IgD+IgMhighCD27+
Switched memory B cells, CD19+IgD-IgM-CD27+
IgA B cells, CD19+IgA+
Plasmablasts, CD19+CD20-CD38highIgM-/low
CD21 low B cells, CD19+CD21lowCD38lowIgM+Results were expressed both as absolute cell counts
and relative percentages.
Statistical analyses
Results were compared by Wilcoxon analysis by using
SigmaStat software version 11.0 (Systat Software, Inc.,
SigmaStat for Windows). All statistical tests were two-
tailed, and a P value <0.05 was considered statistically
significant. When not otherwise indicated, median and
interquartile range (median; IQR) are reported.
Results
Patients’ characteristics
The 160 patients with ANCA-associated vasculitides regu-
larly attending the Department of Rheumatology at the
University Medical Center for Vasculitides in Freiburg,
Germany, were screened for this study. In total, 41 fulfilled
the diagnostic criteria for EGPA. Of the 41 patients with a
diagnosis of EGPA, nine patients had been treated with
RTX for refractory disease activity (n = 8) or relapse (n =
1) on standard immunosuppressive therapy (Table 1). All
nine patients (three women; six men), except for one, had
a five-factor score of ≥1 at diagnosis. Mean age was 45
years (SEM, 5.5 years). All patients were of Caucasian ori-
gin and had systemic disease. Six patients were ANCA
positive on indirect immunofluorescence screening, with a
perinuclear fluorescence pattern in five patients and a
cytoplasmic pattern in one patient. Myeloperoxidase
(MPO) antibodies were present in five patients (Table 1).
Median MPO titer at diagnosis was 108 U/ml (IQR, 64 to
132). Three patients were ANCA negative on indirect im-
munofluorescence screening and in PR3- and MPO-
ELISA. Median concentration of C-reactive protein (CRP)
before induction therapy was 69 mg/L (IQR, 43 to 119)
(normal range below <3.2 mg/L), and median eosinophil
count was 3,118/μl (31%) (IQR, 860 to 6,335). Median
BVAS before induction therapy was 18 (IQR, 13 to 21).
All patients had high disease activity with a baseline BVAS
of ≥10 and pulmonary involvement with asthma in all,
and nonfixed pulmonary infiltrates in seven (73%) of nine
patients. ENT involvement was diagnosed in eight of nine
patients. Neurologic manifestations were found in seven
patients, all presenting with peripheral neuropathy, and
two additionally having central nervous system involve-
ment. Five patients had cardiac involvement with cardio-
myopathy and/or pericarditis. Two patients reported
ischemic cardiac pain, but results of coronary angiography
were normal. Three patients had vasculitic skin lesions,
and three patients had renal involvement (Table 1).
Treatment characteristics of EGPA patients before RTX
therapy
For induction therapy, seven patients were treated with
intravenous cyclophosphamide (CYC) combined with




































1 24 L, ENT, C 2 p 10 10 L↔, ENT↔, C↑ 281 (6.9) 50 None 7.1 15 AZA 19 None
MPO
2 12 L, ENT, C,
PNS
1 (p) 18 18 L↑, ENT↑, C↔, PNS
↔
8,677 (43) 869 AZA 9.8 40 AZA 6 None
(−)
3 66 L, ENT, PNS,
CNS
1 p 14 14 L↓, ENT↔, PNS↑,
CNS↑
663 (6.2) 269 MTX, AZA (−) 10 AZA 6 None
MPO
4 5 L, ENT, C,
PNS, S
2 (−) 28 16 L↔, ENT↔, C↓,
PNS↑, S↓
1,057 (9.7) 1,030 None 10 25 AZA 32 1 more course
at 6 months
(preemptive)(−)
5 16 L, ENT, C 1 (−) 19 19 L↑, ENT↔, C↔ 4,235 (35) 76 MMF, AZA 9.7 20 AZA 34 3 more courses
6 monthly
(preemptive)(−)
6 184 L, ENT, PNS,
S, K
1 p 19 13 L↓, ENT↑, PNS↑, S↑,
K↓
3,542 (22) 17 CYC, AZA,
MTX, LEF
8 7.5 MMF 36 5 more courses
6 monthly
(preemptive)MPO
7 35 L, ENT, C, S,
PNS, CNS, K
1 (−) 36 23 L↑, ENT↓, C↑, S↓,
PNS↔, CNS↓, K↓
8,434 (41) 528 CYC, MTX 12 40 AZA 13 None
(−)
8 7 L, PNS, K 1 p 13 9 L↔, PNS↑, K↓ 2,700 (27) 332 AZA 9.9 15 AZA 6 None
MPO
9 8 L, ENT, PNS 0 c 13 10 L↑, ENT↑, PNS↑ 3,536 (52) 206 MTX (−) 15 MTX 6 None
MPO
The disease duration refers to the time from diagnosis to first RTX treatment. BVAS and organ involvement was evaluated before CYC induction and before the first RTX treatment. Eosinophil counts and IgE
concentration were measured before induction therapy with CYC (n = 7), MTX (n = 1), or AZA (n = 1). Abbreviations for organ involvement: ear nose throat (ENT), cardiac (C), kidney (K), lung (L), peripheral nervous
system (PNS), central nervous system (CNS), and skin (S). FFS, five-factor score; IF, immunofluorescence; ELISA, enzyme-linked immunosorbent assay; BVAS, Birmingham Vasculitis Activity Score. Arrows, organ














Thiel et al. Arthritis Research & Therapy 2013, 15:R133 Page 5 of 9
http://arthritis-research.com/content/15/5/R133glucocorticoids, and one patient each was treated with
AZA (n = 1) or MTX (n = 1) together with glucocorticoids
(Table 1). All patients were refractory to CYC therapy, and
we found no statistically significant decrease in BVAS in-
duced by CYC treatment (P = 0.286; MWU). The patients
were therefore subsequently treated with RTX. In detail,
after a median of three CYC boluses administered
monthly (median dose of 1,000 mg per bolus), four pa-
tients had persistent severe cardiac involvement, five pa-
tients had persistently active or deteriorating peripheral
neuropathy, three patients had increasing pulmonary infil-
trates, and one patient had skin vasculitis. The median
prednisone dose in these patients was 20 mg/day. Add-
itionally, in two patients, ENT involvement had worsened,
and in five patients, symptoms of asthma had increased.
For persisting disease activity, RTX induction regimenFigure 1 Treatment response at a median follow-up of 3 months and
Changes in BVAS (A), daily prednisone dose (B), eosinophils (C), CRP conce
(F) are depicted. ***P < 0.001, **P < 0.01; *P < 0.05.consisting of two infusions of 1 g each, given 2 weeks
apart, was administered. No infusion-related adverse
events occurred. Median CYC sum dose before start of
RTX was 7 g (IQR, 2.75 to 9.8). Median prednisone dose
at the application of RTX was 15 mg/day (IQR, 14 to 29).
In four patients (numbers 1, 4, 5, 8), CYC was continued
as monthly infusions for a further 3 months after RTX
treatment (median sum dose, 7.2; IQR, 5.4 to 7.3), and
then replaced by an oral maintenance immunosuppressive
therapy, whereas in four patients, RTX was directly
followed by azathioprine (125 mg/day), and in one patient,
MTX (15 mg/week) (Table 1). In all but one patient, BVAS
before RTX application was still ≥10, and we found no sta-
tistically significant decrease compared with BVAS before
CYC induction (P = 0.286) (Table 1). The median CRP
concentration was 14 mg/L (IQR, 8 to 36), and median9 months after RTX treatment compared with baseline (BL).
ntrations (D), B-lymphocyte percentages (E), and IgE concentrations
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609 to 2,424) (Figure 1). Immunoglobulin concentrations
for IgG, IgA and IgM before RTX therapy were within
normal range. IgE concentration was increased to 305 IU/
ml (IQR, 128 to 699). B-lymphocyte numbers before ritux-
imab treatment were 193/μl (IQR, 68 to 338).
Treatment response to RTX therapy
At presentation 3 months after RTX treatment, all patients
(n = 9) had responded to RTX treatment, and median
BVAS was 3 (IQR, 2 to 3), with a significant decrease
compared with the median BVAS before RTX (P < 0.001)
(Figure 1). The median decrease in BVAS from the last
measurement before RTX was 10 (IQR, 7 to 12). One pa-
tient was in complete remission (number 1), and eight pa-
tients were in partial remission with persistent neuropathy
(seven patients), and improved or stable ENT symptoms
(two patients). In six patients, asthma symptoms improved
after RTX treatment. Peripheral B cells were measured in
six patients, and all analyzed patients had a complete
B-cell depletion (median 0/μl; IQR, 0 to 1; and 0, IQR, 0
to 0.1). Median prednisone dose was 8.75 mg/day (IQR,
5.5 to 15; P = 0.036). Prednisone could be tapered by me-
dian 9 mg/day (IQR, 5 to 17.5). In six patients, ≤7.5 mg of
prednisone was used as maintenance dose. Two patients
had 10 mg prednisone per day because of residual asth-
matic symptoms, and one patient had 15 mg/day because
of recurrent asthma and increased numbers of eosinophils.
CRP concentration had normalized (P = 0.004) in all
patients, and eosinophil counts had decreased to 245/μl
(4.3%; P = 0.05). IgE concentration normalized in all pa-
tients analyzed (n = 4) (Figure 1). In three patients, MPO
titers were measured 3 months after RTX, and titers were
within normal limits.
Mean follow-up after the first RTX course was 9 months
(SEM, 1.7). Maintenance immunosuppressive therapy
at follow-up analysis was AZA (150 mg/d; n = 7), MTX
(15 mg/d; n = 1), MMF (1,000 mg; n = 1). Within the
9-month observation period, no relapse was recorded, and
the median BVAS was 3 (IQR, 0 to 3) (Figure 1). At the
last available time-point of observation (mean, 9 months)
after the first RTX treatment, CRP concentrations were
within normal limits in all patients, eosinophils had fur-
ther decreased (median, 3.5%; P = 0.007), and IgE concen-
tration was 48 IU/ml (P = 0.034) (Figure 1). Median
prednisone dose was 7.5 mg/d. In no patient could begin-
ning B-cell recovery be observed (Figure 1). Two of the
nine patients (numbers 1 and 7) had a follow-up of more
than 1 year after RTX application (13 months in one, and
19 months in another patient), and both neither relapsed,
nor repopulated their peripheral B-cell compartment
within this observation period. B-cell repopulation has
been described to start between 6 and 9 months after
B cell-depleting therapy. In four patients, the B-cellcompartment was analyzed with high-sensitivity FACS
analysis 6 months after RTX treatment.
None of these patients fulfilled the criteria of B-cell re-
population based on peripheral B-cell numbers and per-
centages. Therefore, a median of 850,000 events was
recorded by FACS analysis to allow high-sensitivity ana-
lysis. In three of the four patients, events in the CD19+
gate were below 100, and these patients were excluded
from further analyses. Only in one patient were we able to
record more than 1,000 events in the CD19 gate. The B-
cell subpopulations identified were mainly plasmablasts
(CD19+CD20-CD38highIgM-/low) and switched memory
B cells (CD19+IgD-IgM-CD27+). No transitional B cells
were detected (data not shown). Three of the nine EGPA
patients (numbers 4, 5, and 6) were subsequently retreated
with RTX after a median of 6 months, as part of a pre-
emptive therapy strategy. At retreatment, none of these
patients had clinical signs of relapse; all had CRP concen-
trations within normal limits, and two patients had slightly
increased but stable numbers of eosinophils. Both patients
with increased numbers of eosinophils were ANCA-
negative (patients 4 and 5), and had no PR3 or MPO anti-
bodies before the initiation of RTX therapy. RTX courses
(2 × 1 g given 2 weeks apart) were administered every 6
months, with two, four, and six courses in one patient each
(Table 1). During the median follow-up time of 3 years in
the patients on preemptive RTX treatment regimens, nei-
ther in the ANCA-positive nor in the ANCA-negative pa-
tients, were relapses observed. One patient (number 4)
had a B-cell repopulation 22 months after the second RTX
course.
Immunoglobulin concentrations
All patients included in this study were evaluated for the
serum immunoglobulin concentrations before RTX ad-
ministration and after RTX treatment. Median immuno-
globulin concentrations for IgG, IgA, and IgM before RTX
therapy were within normal range (IgG, 13.2 g/L; IgA,
1.8 g/L; IgM, 1.2 g/L). After a median time of 24 months
after RTX application, concentrations of immunoglobulins
declined to IgG, 8.8 g/L (P = 0.005), IgA, 1.4 g/L (P =
0.122), and IgM, 0.4 g/L (P = 0.008). At this time, two pa-
tients (22%) had IgG concentrations below the lower limit
of normal (7 g/L). None of the patients showed an in-
crease in IgG concentrations during the observation time.
Adverse events and infections
All patients included into this study were evaluated for
adverse effects over a follow-up of 13 patient-years. RTX
infusions were generally well tolerated, with no adverse
events recorded that impeded the completion of the RTX
infusion. No patient died during follow-up period of the
study. No major infections required hospitalization, and
five minor infections were recorded during the follow-up.
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treated with antibiotics. All patients that had airway infec-
tions had serum IgG concentrations <7 g/L. In one patient
(number 5), a testicular seminoma was diagnosed 12
months after the first RTX course.
Discussion
Eosinophilic granulomatosis with polyangiitis is part of
the ANCA-associated vasculitides but differs in many
aspects from other AAVs like GPA and MPA. Neverthe-
less, the treatment of EGPA is similar to treatment regi-
mens used in GPA and MPA. A recent analysis on the
long-term outcome of 118 patients with EGPA enrolled
in two prospective trials reports a relapse rate of 41% at
a mean of 26 months after treatment onset [9]. This un-
derscores the need for treatment alternatives in EGPA
patients. B cell-targeted therapy with rituximab has suc-
cessfully been introduced into the therapeutic arma-
mentarium of GPA and MPA, but to date, the role of
RTX in EGPA therapy is unclear and based on few case
reports comprising only a very limited number of pa-
tients [10-16]. When included in trials together with pa-
tients like other AAVs like GPA or MPA, EGPA patients
were often not analyzed separately. We report on the
successful treatment of EGPA patients with RTX. Most
patients we report were resistant to conventional induc-
tion treatment with CYC, and some patients had re-
lapsed on maintenance immunosuppressive therapy. All
patients showed a rapid treatment response to rituxi-
mab, with decreasing BVAS, CRP concentration, and eo-
sinophil counts, allowing tapering of prednisone.
Recently, severe bronchospasm associated with rituxi-
mab for refractory EGPA was described in two patients
[26], but no RTX infusion-related adverse events oc-
curred in our patients that received prednisone and anti-
histaminics as comedication. At the evaluation 3 and 9
months after RTX infusion, the most frequent sequelae
were persistent peripheral neuropathy and minor ENT
symptoms that did not completely resolve. Eosinophil
counts did not normalize completely in two ANCA-
negative patients, but both nevertheless had clinically
responded to RTX treatment. After RTX treatment, all
ANCA-positive patients became ANCA negative. All pa-
tients stayed ANCA negative during the follow-up. B-
cell counts were closely monitored in all patients after
RTX treatment. In patients with rheumatoid arthritis
treated with RTX, repopulation of the peripheral B-cell
compartment starts 6 to 9 months after RTX therapy
with an initial increase in transitional B cells. We ana-
lyzed four patients 6 months after RTX therapy with
high-sensitivity FACS analysis, and found a persisting
complete B-cell depletion in three patients. In one patient,
few remaining switched memory B cells and plasmablasts
but no transitional cells were found that would indicate astarting process of repopulation. Three of the nine EGPA
patients were preemptively retreated with RTX. During
the subsequent median follow-up time of 3 years, no re-
lapse was observed. In these three patients, B cells were
closely monitored during the follow-up time. Only one pa-
tient had a B-cell repopulation 22 months after the second
RTX course. As our patients were initially treated with
CYC and then with an oral maintenance immunosuppres-
sive therapy after RTX, this may contribute to the delayed
B-cell repopulation. Further studies assessing the repopu-
lation kinetics of B cells after RTX treatment of EGPA pa-
tients are necessary.
During the follow-up of 13 patient-years, no major in-
fections were recorded. In one patient, a testicular
seminoma was diagnosed 12 months after the first RTX
course, but most likely was unrelated to RTX treatment.
Five minor infections related to the upper respiratory
tract occurred during follow-up. As the patients in
whom the minor infections were recorded had serum
IgG concentrations slightly below the normal range, and
we recently reported a decrease in serum immunoglobu-
lin concentrations that may follow RTX treatment in
AAV patients pretreated with CYC [27], we suggest that
serum immunoglobulin concentrations should be mea-
sured regularly. A further evaluation addressing specific
antibody production in EGPA patients after CYC/RTX
treatment will help to assess the relevance of the de-
crease in serum immunoglobulins.
No opportunistic infections occurred in the patients
we report. Furthermore, RTX treatment allowed a rapid
tapering of daily prednisone, a major risk factor for in-
fectious complications.
ANCA status separates two EGPA phenotypes that dif-
fer in organ manifestations, with renal and peripheral ner-
vous system involvement being more common in ANCA-
positive EGPA patients, whereas for ANCA-negative
patients, an association with cardiac and gastrointestinal
involvement, as well as pulmonary infiltrates, has been
reported [17,28,29]. The presence of ANCA in EGPA
pathogenetically differentiates a vasculitic form of the dis-
ease from an eosinophil-driven disease entity. The pres-
ence of ANCA suggests an involvement of B cells in
disease pathogenesis and may provide a rationale for the
use of a B cell-depleting therapeutic strategy. The rationale
for the use of B-cell depletion in ANCA-negative EGPA
patients seems to be less clear, but for all EGPA patients, a
strong IgG4 immune response, irrespective of their ANCA
status, has been described [18]. To our knowledge, very
few ANCA-negative EGPA patients treated with rituximab
have so far been described in the literature [11]. For GPA
and MPA, it has been demonstrated that ANCA-negative
patients can achieve remission with rituximab [30]. Fur-
thermore, evidence of cross-talk between B cells and eo-
sinophils and B cells has been described to be able to
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phils [32]. Our study includes three ANCA-negative
EGPA patients. All ANCA-negative patients responded to
RTX therapy. Two ANCA-negative patients were treated
with RTX as induction therapy, followed by RTX com-
bined with azathioprine for maintenance therapy. As men-
tioned earlier, eosinophil counts decreased after RTX
treatment but did not normalize completely in these two
patients. Nevertheless, all ANCA-negative patients that
initially had been resistant to a conventional immunosup-
pressive therapy, including cyclophosphamide, responded
to RTX treatment. They achieved a partial remission only,
with persistent symptoms of neuropathy. In the two pa-
tients re-treated with RTX preemptively, the treatment re-
sponse was sustained during the whole follow-up period.
Our study has the limitation that the number of patients
included and the follow-up time are limited. Therefore, we
cannot draw valid conclusions from our data regarding
long-term relapse-rate and infectious complications. Fur-
thermore, seven of the nine patients reported were treated
with CYC before RTX, and it cannot completely be ex-
cluded that a delayed effect of the CYC treatment contri-
buted to the therapeutic response observed after RTX
administration. But, as all patients reported had CYC-
refractory disease after a median of three CYC i.v. boli,
demonstrating a clear treatment failure of CYC, it does
not seem plausible that the distinct treatment response
observed after RTX administration is due to a protracted
effect of the CYC treatment. Additionally, the patients in-
cluded in the study were Caucasians from a single center.
In our opinion, our study indicates that RTX is an effective
therapy even in patients refractory to CYC, but because of
the retrospective design and the limited number of pa-
tients included in our study we cannot deduce from our
data whether a second immunosuppressant given con-
comitant with RTX is useful. Conversely, the strength of
our study is that it is has no selection bias, as we report on
a complete cohort of EGPA patients. In this way, our work
differs from previous case reports. For case reports, it can
never be ruled out that a selection bias exists, and pre-
dominantly patients with positive treatment responses are
reported, whereas patients that did not respond to therapy
are published less frequently.Conclusion
Our data on patients with EGPA resistant to standard ther-
apy indicate that rituximab is an efficient and safe treatment
for ANCA-positive and potentially also for ANCA-negative
patients with EGPA. Preemptive retreatment with RTX
combined with standard maintenance immunosuppressants
resulted in a sustained treatment response. Prospective,
randomized trials evaluating the use of RTX in EGPA
are warranted.Abbreviations
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